Lv11
30 积分 2026-07-02 加入
Myasthenia gravis: Molecular mechanisms and promising therapeutic strategies
6小时前
已完结
FcRn inhibitors: Transformative advances and significant impacts on IgG-mediated autoimmune diseases
1天前
已完结
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial
1天前
已完结
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
1天前
已完结
皖公网安备34019202002308
